Refractory anemia with ringed sideroblasts (RARS) associated with marked thrombocytosis (RARS-T) has clinical and pathologic features of both RARS and essential thrombocytosis (ET). It has been uncertain whether this disease represents a variant of RARS, a variant of ET, or the simultaneous occurrence of two separate disorders (RARS and ET). The recently adopted World Health Organization (WHO) Classification of Hematopoietic and Lymphoid Neoplasms recognized a category of myelodysplastic syndrome/myeloproliferative diseases (MDS/MPD) with clinical, laboratory and morphologic features of both MDS and MPD. RARS-T has been assigned to the MDS/MPD-unclassifiable (MDS/MPD-U) subcategory as a provisional diagnosis in the new WHO classification scheme. A more definitive understanding of the pathogenesis of this syndrome may provide useful prognostic information and suggest potential therapeutic approaches to these patients.
The V617F-activating mutation in the janus kinase 2 (JAK2) tyrosine kinase appears to be a critical event associated with the pathogenesis of most BCR/ABL-negative MPD. [1] [2] This mutation has been found in 65-97% of patients with polycythemia vera, 23-57% patients with essential thrombocythemia (ET) and 35-50% patients with primary myelofibrosis (MF). In mouse models, JAK2 V617F mutation can lead to constitutive activation of signal transducers and activators of transcription 5, cytokineindependent growth of colony-forming units-erythroid (CFU-E) and erythropoietin hypersensitivity resulting in erythrocytosis. 1 Recently, Steensma et al. 3 reported that the V617F JAK2 mutation is an infrequent event in MDS or CMML, with a frequency of 5% (3/119) and 3% (5/101), respectively. The rarity of the V617F JAK2 mutation in MDS has also been noted by several other groups. 4, 5 This study is to investigate the clinical, cytogenetic, morphological features and JAK2 mutational status in RARS-T patients, in comparison to other closely related hematological disease groups. A total of 103 cases of MDS by French-AmericanBritish (FAB) criteria with platelets 4400 Â 10 9 /l (at the time of presentation or during the early phase of the disease) were identified among 1510 consecutive MDS patients diagnosed at or referred to Rush University Medical Center (RUSH) and University of Massachusetts Medical Center (UMASS) over a 10-year period (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) . RUSH and UMASS are both tertiary referral centers for MDS treatment. The cases were subsequently classified according to WHO criteria into the following distinct groups: (1) RARS-T: RARS with platelets X600 Â 10 9 /l; (2) RARS with mild thrombocytosis: RARS with platelets 400-600 Â 10 9 /l; (3) MDS/MPD-U: MDS without ringed sideroblasts but with platelets X600 Â 10 9 /l; (4) other types of MDS with mild thrombocytosis: MDS without ringed sideroblasts but with platelets 400-600 Â 10 9 /l and (5) isolated 5qÀ syndrome with thrombocytosis (platelets 4400 Â 10 9 /l). Thirty ET cases were obtained from Massachusetts General Hospital (MGH) for comparison. Among the 103 MDS patients with ringed sideroblasts and thrombocytosis, the majority (27/37, 73%) had mild thrombocytosis whereas only 10/37 (27%) were classified as RARS-T. To further characterize the latter entity, an additional six cases of RARS-T were obtained from MGH and were included in this group. One of the six cases was previously published as a Case Record of MGH. 6 The remaining patients included 14 (14%) with isolated 5qÀ syndrome (nine with platelets 400-600 Â 10 9 /l and five with platelets X600 Â 10 9 /l), 16 (16%) with MDS/MPD-U and 36 (35%) with other types of MDS (RA, RAEB-1, RAEB-2). The MDS patients with thrombocytosis showed clinicopathologic features similar to corresponding MDS cases with normal or low platelet counts (data not shown); because of the specific focus of this study, this group of patients was not included in the final analysis. The classification results are shown in Table 1 .
The clinical and hematologic data are listed in Table 2 . All patients were adults and there was no significant age differences found between the groups. RARS-T patients showed a male predominance (M:F ¼ 12:4), whereas the isolated 5qÀ syndrome patients showed a female predominance (M:F ¼ 3:11). The RARS-T patients showed more pronounced anemia than ET patients, but were less anemic or neutropenic than all other patient groups (Po0.01). The MDS/MPD-U group of patients had a higher blast count (Po0.01) and international prognostic scoring system (IPSS) risk category (Pp0.05) compared to all other patient groups.
The bone marrow specimens were independently reviewed by three hematopathologists blinded to the original diagnoses, who independently scored the bone marrow cellularity, reticulin fibrosis grade, ringed sideroblast percentage, megakaryocyte number and megakaryocyte morphology. Case Letters to the Editor classification was by consensus of the three hematopathologists. Most of the bone marrows were hypercellular. The cellularity was comparable among all groups, except for the isolated 5qÀ syndrome patients, who showed a lower overall cellularity (Po0.01). A feature common to all RARS cases with thrombocytosis was the presence of more than 15% ringed sideroblasts, ranging from 20 to 475% of the nucleated erythroid elements. The percentage of ringed sideroblasts did not differ between RARS-T and RARS with mild thrombocytosis. An increase in megakaryocytes was found in most of the cases, but with a remarkable variety of histologic and cytological characteristics. Of the15 RARS-T cases with available biopsy slides for evaluation, three showed MDS-like megakaryocytes; two ET-like; six mixed MDS-and ET-like; three mixed ETand CIMF-like; and one mixed CIMF-and MDS-like. The consensus on megakaryocyte morphological group assignment was low at initial blind review among three hematopathologists owing to many mixed features of megakaryocytes in RARS-T cases, but consensus was ultimately reached after standardizing the criteria. In contrast, of the 26 patients with RARS and mild thrombocytosis, 16 showed normal or near-normal morphology; six showed MDS-like; one mixed MDS-and ET-like; and three ET-like. In the 14 MDS/MPD-U patients, three showed near-normal megakaryocyte morphology; nine MDS-like; and two mixed ET/CIMF-like. The megakaryocytes in the isolated 5qÀ syndrome were mainly MDS-like mononucleated megakaryocytes. Evaluation of the silver impregnation stain revealed that most RARS-T patients had normal or mildly to moderately increased reticulin. There was no significant difference in reticulin fibrosis level among the five groups.
Karyotypic data are summarized in Table 2 . Among RARS-T patients, conventional karyotyping was normal in 11/15 (73%) and abnormal in four patients (27%), including two with trisomy 8, one with del(11)(q23) and one with a complex karyotype. Among patients with RARS with mild thrombocytosis, 18/23 showed a normal karyotype (78%); 5/23 (22%) cases had abnormal karyotypes, including two with isolated trisomy 8, one with del(7q) (q12q21) and two with complex karyotypes containing del(5q). Among MDS/MPD-U patients, 6/14 (43%) abnormal karyotypes were identified: five had a complex karyotype, and four of which contained del(5q). Neither inv(3)(q21q26) nor t(3;3)(q21;q26) were detected in the MDS/MPD-U group. All isolated 5qÀ syndrome patients by definition had a sole cytogenetic abnormality involving the long arm of chromosome 5, with variable deletions between 5q13 to 5q33.
The majority of these patients were in the low-risk IPSS groups (Table 2) , with the exception of the MDS/MPD-U patients (Group 3), who had a higher risk IPSS score relative to RARS-T (Pp0.05), mainly attributed to high-risk cytogenetics and increased blast counts. However, the IPSS risk may have been underestimated in all patients owing to the (by definition) absence of thrombocytopenia.
Mutation JAK2 V617F was analyzed by mutation-specific polymerase chain reaction and direct sequencing on frozen bone marrow samples or peripheral blood. 3, 4 The JAK2 V617 mutation was detected in 6/12 (50%) RARS-T cases, where the sequence chromatograms displayed peaks from both wild-type and mutant genomic DNA at codon 617. No JAK2 V617 mutation was detected in patients in any other groups, including 19 patients with RARS and mild thrombocytosis, 11 patients Table 2 Clinicopathologic characteristics of patients with RARS-T, in comparison with patients with other myeloid diseases associated with thrombocytosis Letters to the Editor in the MDS/MPD-U group and four patients with isolated 5qÀ syndrome and marked thrombocytosis.
The major clinicopathological features, cytogenetic findings and JAK-2 V617F mutation status were compared between RARS-T cases with mutant and wild-type JAK2. There was no significant difference in hematological features (such as hemoglobin levels, leukocyte counts or degree of thrombocytosis) nor were there differences in the morphological or cytogenetic findings.
The median follow-up time of all patients was 66 months (Figure 1) . The median overall survival (OS) of RARS-T patients was 88 months, which was not statistically different from RARS with mild thrombocytosis (101 months). In contrast, the median survival of RARS-T was inferior to ET patients (median survival not yet reached) (P ¼ 0.046). The median survival observed in RARS-T appeared better than MDS/MPD-U (44 months) and worse than isolated 5qÀ syndrome (125 months); however, these differences were not statistically significant by log-rank test (P ¼ 0.09 and P ¼ 0.18, respectively).
Discussion:
In this study, we demonstrated that a significant proportion of RARS-T cases show the JAK2 V617F mutation (6/12, 50%) if these cases are selected using the proposed criteria in the latest WHO Classification (platelet count 4600 Â 10 9 /l). The JAK2 V671F mutation was not seen in other types of MDS with thrombocytosis, including RARS with mild thrombocytosis, isolated 5qÀ syndrome with thrombocytosis and MDS/MPD-U with thrombocytosis.
As the new WHO Classification included RARS-T as a provisional diagnosis in the MDS/MPD-U subcategory, two original studies on this entity have been published. 7, 8 In these two studies, RARS-T was defined as RARS with platelets X500 Â 10 9 /l, not conforming precisely to the WHO criteria (X600 Â 10 9 /l). The rationale behind using the lower limit was that a number of patients with ET can present with that platelet count at the initial stage. However, it was unclear how many cases of a platelet count between 500 and 600 Â 10 9 /l were included and which, if any, eventually showed a platelet count in excess of 600 Â 10 9 /l during the course of the disease. Our study showed that patients with RARS-T had significantly higher Hb levels, peripheral white cell count (WBC) and absolute neutrophil count (ANC) than RARS with mild thrombocytosis, suggesting that RARS-T has more 'proliferative' clinical features than RARS with mild thrombocytosis. Morphologically, the megakaryocytes in RARS with mild thrombocytosis appeared relatively normal, in contrast to those in RARS-T, which often showed a spectrum from MDS-like to MPD-like or mixed features. Based on our data, we propose that RARS-T and RARS with mild thrombocytosis are likely to be different diseases, and the strict thrombocytosis criteria proposed by WHO Classification (4600 Â 10 9 /l) should be used for an accurate categorization of these cases.
The JAK2 V617F mutation frequency we have demonstrated in RARS-T cases is significantly higher than that seen in MDS, [3] [4] [5] and is similar to the frequencies demonstrated in CIMF and ET. 2 Tiu R et al. (presented at American Society of Hematology Annual Meeting, 2005, Atlanta, GA) recently also reported that 3/3 (100%) RARS with thrombocytosis showed the JAK2 V617F mutation. In the study conducted by Steensma et al., 3 of the five JAK2-mutated MDS cases, one showed marrow fibrosis and two were classified as RARS. However, information about the platelet counts in those two RARS cases was not provided. Nevertheless, based on these findings, we suspect that the activating JAK2 mutation is driving hematopoietic cell proliferation in RARS-T, similarly to MPDs, and thus leading to a degree of growth factor independence. 1 The JAK2 V617F mutation has also been reported to be an infrequent event in MDS/MPD diseases such as CMML, atypical cell mediated lympholysis and juvenile myelomonocytic leukemia. [3] [4] [5] In our study, the JAK2 V617F mutation was not found in any of the 11 cases of MDS/MPD-U with thrombocytosis tested. These results indicate that the proliferative capacity in most mixed MDS/MPD cases is likely not mediated through the V617 JAK2 mutation. The aberrant proliferative signal in these JAK2-unmutated cases remains unknown.
Before the WHO proposal, RARS-T had also been frequently considered as a type of MPD, so-called ET with ringed sideroblasts (ET/RS) owing to the combination of thrombocytosis and RS. Based on our JAK2 V617F mutation data, the question arises if RARS-T is indeed of an ET origin with secondary RS. Our cases of RARS-T had lower platelet counts, lower Hb levels, higher mean corpuscular volume (data not shown), and inferior survival than ET patients. The megakaryocyte morphology also differed between these two groups of patients. Similar clinicopathological observations were also reported by Shaw; [ 7 however, their study used different diagnostic criteria for inclusion, such as o3% blasts and normal cytogenetics, which might select a group of patients with a more favorable prognosis. Schmitt-Graeff et al.
8 studied 38 patients with a diagnosis of 'ET' (platelet X500 Â 10 9 /l) and associated RS. They showed that these cases could be sub-classified into cases of ET, chronic idiopathic myelofibrosis (CIMF) (pre-fibrotic stage), and MDS based on morphology alone. We acknowledge the morphologic variety of megakaryocytes described in their series, but feel it is difficult to assign the patients into a definitive group based on megakaryocyte morphology alone, as the many of our cases in fact showed mixed megakaryocyte features of ET/CIMF, ET/MDS or CIMF/MDS.
Cytogenetics is a crucial ancillary diagnostic test that is typically performed in all cases of suspected MDS or MPD. In our study, one patient with isolated 5qÀ syndrome presented with RARS and a platelet count of 4600 Â 10 9 /l and was indistinguishable from RARS-T clinically, underscoring the importance of cytogenetics in separating these entities. Patients in the MDS/MPS-U thrombocytosis group generally showed less favorable prognostic karyotype abnormalities and had a higher IPSS score. Interestingly, five out of seven MDS/MPD-U and both RARS with mild thrombocytosis cases with a complex Kaplan-Meier survival curves of five patient groups. OS of RARS-T (n ¼ 16) is shorter than ET patients (n ¼ 30) (log-rank test: P ¼ 0.046), comparable to RARS with mild thrombocytosis (n ¼ 27) (P ¼ 0.47). The statistical difference in OS between RARS-T vs isolated 5qÀ syndrome (n ¼ 14) (P ¼ 0.18) or MDS/MPD-U could not be found (P ¼ 0.09).
Letters to the Editor karyotype contained a del(5q) abnormality; the underlying mechanism of megakaryocytic proliferation in these cases and their relationship to the entity MDS with 5qÀ remains unknown.
In summary, we have demonstrated that RARS-T shows clinicopathologic features of both MDS and MPD, but it differs from the subgroup of MDS/MPD-U clinically and in its association with the JAK2 V617F mutation. Based on the frequency of JAK2 mutations in the groups we studied, we also propose that RARS-T and RARS with mild thrombocytosis are likely to be different diseases and the strict thrombocytosis criteria proposed by WHO Classification (4600 Â 10 9 /l) is recommended for accurate categorization of this entity. The ease of screening for the JAK2 V617F mutation makes it an attractive tool for diagnostic purposes, and this group of patients may benefit from the development of therapeutic approaches that target the JAK2 tyrosine kinase.
Approximately 45% of patients with de novo acute myeloid leukemia (AML) have a normal karyotype (nk-AML). 1 The complete remission (CR) rates for this group are around 80% with 5 years survival of 40-50%. The molecular heterogeneity of nk-AML has been recently described and may relate to prognostic stratification and new therapeutic approaches. 2 Recently, Falini et al. 3 reported a high incidence of heterozygous mutations in the gene coding for nucleophosmin (NPM), particularly in nk-AML. All mutations are located in exon 12 and are predicted to alter the protein structure at its C-terminal, causing delocalization of NPM from its normal nucleolar stores to the cytoplasm. Since this initial publication, six reports have investigated the prognostic value of NPM mutations in AML and consistently report better event-free survival (EFS) and overall survival (OS) in patients with mutated NPM (NPMm). 4, 5 However, the good prognostic impact of NPM mutations may be hampered by its association to internal duplication of FLT3 (FLT3-ITD) mutations, which generally correlate with a worse outcome. Indeed, the favorable impact of NPM mutations on OS and EFS was detected only in the NPMm/FLT3-ITD À subgroup of patients. Here, we analyzed the clinical spectrum and prognostic value of NPM mutations in 110 patients with de novo nk-AML.
Detection of NPM gene mutations was carried out on genomic DNA by polymerase chain reaction and genescan analysis. NPM mutations were detected in 46% of patients. In 27 patients analyzed by immunofluorescence staining for NPM localization, a 100% correlation with the NPM mutational status was observed. NPM mutations were significantly correlated with female gender (P ¼ 0.02) and CD34 expression (P ¼ 0.001) ( Table 1 ). There was no statistical difference between NPMm and NPM wild-type (NPMwt) patients when considering the age, French-American-British classification subgroups, white blood cell (WBC) count, FLT3-ITD mutation, bone marrow blasts infiltration and myelodysplastic syndrome-related features. FLT3-ITD mutations were determined in 107 patients. There
